Lbp Am Sa Reduces Stock Position in Cigna Group $CI

Key Points

• Lbp Am Sa reduced its holdings in Cigna Group by 15.1%, selling 4,770 shares, and currently owns 26,785 shares valued at approximately $8.85 million.
• Insider Nicole S. Jones sold 28,526 shares of Cigna Group stock, representing a 52.66% decrease in her ownership, with proceeds totaling over $8.55 million.
• Cigna Group reported $7.20 earnings per share for the last quarter, surpassing the consensus estimate by $0.05, with a revenue increase of 11.0% year-over-year.

Lbp Am Sa reduced its position in shares of Cigna Group (NYSE:CI - Free Report) by 15.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,785 shares of the health services provider's stock after selling 4,770 shares during the period. Lbp Am Sa's holdings in Cigna Group were worth $8,855,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Flaharty Asset Management LLC purchased a new stake in shares of Cigna Group during the first quarter worth about $28,000. 1248 Management LLC bought a new position in Cigna Group in the first quarter worth about $29,000. Activest Wealth Management raised its stake in Cigna Group by 360.0% in the first quarter. Activest Wealth Management now owns 92 shares of the health services provider's stock worth $30,000 after buying an additional 72 shares in the last quarter. Retirement Wealth Solutions LLC raised its stake in Cigna Group by 74.1% in the second quarter. Retirement Wealth Solutions LLC now owns 101 shares of the health services provider's stock worth $33,000 after buying an additional 43 shares in the last quarter. Finally, Saudi Central Bank bought a new position in Cigna Group in the first quarter worth about $36,000. 86.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Cigna Group

In related news, insider Nicole S. Jones sold 28,526 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $300.00, for a total value of $8,557,800.00. Following the sale, the insider owned 25,648 shares in the company, valued at approximately $7,694,400. This trade represents a 52.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.70% of the company's stock.

Cigna Group Trading Up 1.1%

NYSE:CI opened at $291.36 on Thursday. Cigna Group has a 52 week low of $256.89 and a 52 week high of $358.88. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 0.65. The company's 50 day moving average price is $292.05 and its 200-day moving average price is $310.02. The stock has a market cap of $77.77 billion, a price-to-earnings ratio of 15.90, a PEG ratio of 0.84 and a beta of 0.46.

Cigna Group (NYSE:CI - Get Free Report) last issued its earnings results on Thursday, July 31st. The health services provider reported $7.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.15 by $0.05. Cigna Group had a net margin of 1.92% and a return on equity of 18.80%. The company had revenue of $67.13 billion for the quarter, compared to analysts' expectations of $62.61 billion. During the same quarter last year, the company posted $6.72 earnings per share. The firm's quarterly revenue was up 11.0% on a year-over-year basis. Cigna Group has set its FY 2025 guidance at 29.600- EPS. On average, equities research analysts forecast that Cigna Group will post 29.77 earnings per share for the current fiscal year.

Cigna Group Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 18th. Investors of record on Thursday, September 4th were issued a $1.51 dividend. The ex-dividend date was Thursday, September 4th. This represents a $6.04 annualized dividend and a yield of 2.1%. Cigna Group's dividend payout ratio (DPR) is currently 32.97%.

Analyst Upgrades and Downgrades

CI has been the subject of a number of research reports. Barclays increased their price target on shares of Cigna Group from $354.00 to $383.00 and gave the stock an "overweight" rating in a research note on Thursday, September 4th. Deutsche Bank Aktiengesellschaft set a $415.00 price target on shares of Cigna Group and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Royal Bank Of Canada reissued an "outperform" rating and issued a $371.00 price target on shares of Cigna Group in a research note on Thursday, June 26th. Guggenheim reissued a "buy" rating and issued a $350.00 price target (down from $388.00) on shares of Cigna Group in a research note on Monday, August 4th. Finally, Wells Fargo & Company decreased their target price on shares of Cigna Group from $341.00 to $340.00 and set an "equal weight" rating for the company in a research note on Thursday, August 14th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Cigna Group currently has a consensus rating of "Buy" and a consensus price target of $371.81.

About Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.